172 related articles for article (PubMed ID: 12377642)
1. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Laack E; Köhler A; Kugler C; Dierlamm T; Knuffmann C; Vohwinkel G; Niestroy A; Dahlmann N; Peters A; Berger J; Fiedler W; Hossfeld DK
Ann Oncol; 2002 Oct; 13(10):1550-7. PubMed ID: 12377642
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer.
Ertan E; Soydinc H; Yazar A; Ustuner Z; Tas F; Yasasever V
Tumori; 2011; 97(3):286-9. PubMed ID: 21789004
[TBL] [Abstract][Full Text] [Related]
3. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
4. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Mihaylova Zh; Ludovini V; Gregorg V; Floriani I; Pistola L; Toffaneti F; Ferraldeschi M; Spreafico A; Ceresoli GL; Bellet M; Darwish S; Tonato M; Raynov J
J BUON; 2007; 12(1):105-11. PubMed ID: 17436410
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer.
Trapé J; Buxó J; de Olaguer JP
Clin Chem; 2003 Mar; 49(3):523-5. PubMed ID: 12600977
[No Abstract] [Full Text] [Related]
9. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
Brattström D; Bergqvist M; Hesselius P; Larsson A; Lamberg K; Wernlund J; Brodin O; Wagenius G
Lung Cancer; 2002 Jul; 37(1):57-63. PubMed ID: 12057868
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Choi JH; Kim HC; Lim HY; Nam DK; Kim HS; Yi JW; Chun M; Oh YT; Kang S; Park KJ; Hwang SC; Lee YH; Hahn MH
Lung Cancer; 2001; 33(2-3):171-9. PubMed ID: 11551412
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Krajnik G; Mohn-Staudner A; Thaler J; Greil R; Schmeikal S; Marhold F; Deutsch J; Preiss P; Malayeri R; Schäfer-Prokop C; Wein W; Huber H; Pirker R
Ann Oncol; 2000 Aug; 11(8):993-8. PubMed ID: 11038036
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
Katakami N; Sugiura T; Nogami T; Yamamoto H; Negoro S; Nakano T; Okamoto N; Takada Y; Kodama K; Ariyoshi Y
Lung Cancer; 2004 Jan; 43(1):93-100. PubMed ID: 14698543
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
Grigorescu A; Ciuleanu T; Firoiu E; Muresan DR; Teodorescu G; Basson BR
Lung Cancer; 2007 Aug; 57(2):168-74. PubMed ID: 17467848
[TBL] [Abstract][Full Text] [Related]
14. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study.
Recchia F; Lombardo M; De Filippis S; Rosselli M; Rea S
Anticancer Res; 2002; 22(2B):1321-8. PubMed ID: 12168945
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
[TBL] [Abstract][Full Text] [Related]
18. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
McGirt MJ; Lynch JR; Blessing R; Warner DS; Friedman AH; Laskowitz DT
Neurosurgery; 2002 Nov; 51(5):1128-34; discussion 1134-5. PubMed ID: 12383357
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J
Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125
[TBL] [Abstract][Full Text] [Related]
20. Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
Comella P
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):35-40. PubMed ID: 10960944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]